In today’s Bulldog wrapup of technology and life science news:

  • Bill Gates doesn’t back Apple in phone dispute
  • Bioventus acquires distribution rights to an osteoarthritis pain treatment
  • Biocryst shares drop
  • Heat Bio faces de-listing

The details:

  • Gates doesn’t back Apple

Bill Gates is siding against Apple — and many other technology companies — in saying the firm should help the U.S. government to hack into a locked iPhone as part of an investigation into the San Bernardino shooting.

Apple has resisted providing a piece of programming that would help the FBI access the phone. Apple argues that governments, both in the U.S. and overseas, are likely to use the program in other cases, undermining data privacy.

In an interview Tuesday with the Financial Times, Microsoft founder Gates says “this is a specific case where the government is asking for access to information.” He likened it to the police getting records from a phone company.

The heads of many tech companies like Facebook, Twitter and Google have sided with Apple.

  • Bioventus acquires osteoarthritis pain treatment

Triangle-based Bioventus has acquired U.S. distribution rights for the rights to an osteoarthritis of the knee pain reliever from IBSA, a Swiss pharmaceutical firm.

Financial terms were not disclosed.

Read more at:

http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=154330#.VsyOvvkrKM8#ixzz410k8wcuF

  • ​Biocryst financial report triggers stock drop

Shares in Biocryst (Nasdaq: BCRX) fell more than 6 percent Tuesday after the company reported a 25 cent-per-share loss.

The company reported a $43 million loss for the year and income of $48 million.

For details, see:

https://beta.finance.yahoo.com/news/biocryst-reports-4q-loss-121905867.html

  • Heat Bio faces de-listing

The falling value of Chapel Hill-based Heat Bio’s (Nasdaq: HTBX) has triggered a preliminary warning about a possible de-listing.

Read The Triangle Business Journal report at:

http://www.bizjournals.com/triangle/news/2016/02/23/heat-biologics-htbx-faces-delisting-nasdaq-stock.html?ana=yahoo